Mecidal

Mebhydrolin

Method of action: Antiallergic

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mecidal

Property	Description
Active ingredient	Mebhydrolin (as Napadisilate)
Form	Tablet, Syrup
Pharmacological class	First-generation Histamine H1-receptor antagonist
Common use	Systemic relief of allergic symptoms
Origin	Synthetic organic compound

What Type of Medicine is Mecidal (Mebhydrolin)?

Mecidal is a synthetic pharmaceutical preparation intended for systemic use, whose active ingredient, Mebhydrolin, is classified as a first-generation antihistamine that acts as an H1-receptor antagonist. The drug's identity is defined by its core mechanism of interfering with the allergic processes initiated by the mediator histamine throughout the body. Mebhydrolin inhibits histamine response and is characterized by a rapid onset of action against acute allergic events.

The substance itself is a synthetic organic compound, specifically a derivative of N-alkylindole, confirming it is manufactured rather than naturally sourced. Mecidal's formulation is typically a single-ingredient product, ensuring its therapeutic action centers exclusively on Mebhydrolin’s established profile.

Mecidal Dosage Forms and General Therapeutic Purpose

Mecidal is intended for oral administration and is commonly supplied as both a solid tablet and a liquid syrup preparation. The inclusion of a syrup form is often a key differentiating factor, making the preparation suitable for patients, including children, who may have difficulty swallowing tablets.

The general therapeutic purpose of Mecidal is to function as an antiallergic agent, providing systemic relief from the manifestations of histamine release. This confirms Mecidal's primary role in easing the discomfort caused by generalized allergic responses, such as the acute itching associated with urticaria. By effectively blocking histamine from engaging with its receptors, the drug helps mitigate symptoms and is often used when a systemic, established antihistamine effect is required.

What side effects are possible with Mecidal?

Possible Side Effects and Safety Information

The official safety profile for Mecidal (Mebhydrolin) is documented in regulatory sources based on observed adverse reactions and inherent drug properties.

Documented Adverse Reactions

The most frequently reported reactions are classified as common in official prescribing information and primarily involve the central nervous system and gastrointestinal tract. These typically include drowsiness (sedation), fatigue, and impaired coordination, alongside dry mouth, nausea, and abdominal discomfort. Uncommon effects documented in the regulatory safety profile include agitation, dizziness, and tremor, categorized under Nervous System or Psychiatric Disorders.

Adverse effects associated with the drug's anticholinergic properties include visual disturbances and difficulty with micturition (urinary retention), as described in official labeling.

Classification	Examples of Officially Documented Effects
Common	Drowsiness, Dry mouth, Fatigue, Nausea, Impaired coordination
Uncommon	Agitation, Tremor, Headache, Dizziness

Serious Adverse Reactions and Safety Constraints

Regulatory documentation outlines that rare but serious adverse reactions are possible. These include severe hypersensitivity reactions such as angioedema or anaphylaxis. The drug's safety information also documents the risk of rare but clinically significant blood dyscrasias, specifically mentioning agranulocytosis and thrombocytopenia.

Safety notes specify that older adults may exhibit increased susceptibility to the sedative effects, resulting in enhanced confusion or dizziness, and are also more vulnerable to anticholinergic effects like urinary retention. Official constraints advise that the use of Mecidal with other central nervous system depressants, including alcohol, may result in additive sedation.

Overdose and Emergency Response

Mecidal Overdose and when to seek help: Official Regulatory Information

This information describes the documented risks and required emergency actions for Mecidal overdose, based strictly on authoritative governmental regulatory documents (e.g., FDA, EMA).

Documented Overdose Presentations

Classification	Manifestations Described in Labeling
Central Nervous System	Excessive sedation, profound CNS impairment, coma, seizures.
Cardiopulmonary	Severe hypotension (low blood pressure), respiratory depression, cardiac arrest.
Population Specific	Pediatric patients and individuals with hepatic impairment may have increased susceptibility to prolonged and severe toxicity.

Required Emergency Action

Overdose of Mecidal is classified as potentially serious and life-threatening, primarily due to the risk of respiratory and cardiovascular collapse. Immediate professional medical attention is mandatory.

When to Seek Urgent Help (Label-Derived Phrasing Only):

Upon suspicion of overdose or the appearance of any signs of toxicity, particularly difficulty breathing, loss of consciousness, or severe dizziness, patients or caregivers must immediately contact a Poison Control Center or emergency medical services and transport the individual to an emergency facility.

Management and Monitoring

Management is primarily supportive, aimed at maintaining adequate ventilation and cardiovascular function. The regulatory information for Mecidal notes the existence of [Specific Antidote Name] as a pharmacological agent that can be administered for the reversal of central effects. Continuous cardiac monitoring and close observation of respiratory status are required in a clinical setting.

Therapeutic Uses of Mecidal

Mecidal is generally used for symptomatic relief in conditions driven by allergic processes, aiming to ease patient discomfort and contribute to day-to-day stability during symptom flare-ups. The medication is indicated for the management of conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria.

This medication is applied across domains where additional symptomatic support is needed, primarily addressing symptoms related to physical discomfort from cutaneous allergic manifestations like intense itching (pruritus), hives, and localized swelling, as well as upper respiratory symptoms including persistent sneezing, watery eyes, and excessive rhinorrhea. It is used to address symptom clusters that interfere with daily functioning and is relevant in situations requiring short-term symptomatic support for generalized allergic episodes.

Quick Fact: Relief for Pruritus and Seasonal Symptoms Mecidal is relevant in conditions characterized by periods of heightened symptoms, commonly applied during phases of increased distress or discomfort associated with allergic flare-ups.

Regulatory References

NIH PubChem Pathway Overview

Eligibility and Restrictions for Use

The eligibility profile for Mecidal (Mebhydrolin) is defined by clear constraints established in official government regulatory documents. The medicine is primarily approved for use in Adults, Adolescents, and Children starting from two years of age.

Use is strictly Contraindicated in several groups. These include patients with known Hypersensitivity to the drug or its ingredients, Newborns or Babies, and individuals diagnosed with Porphyria. Specific clinical conditions also prohibit use, notably Gastric Ulcers or Gastric Infections.

For other populations, use is classified as Not Recommended or requires Caution. Use is Not Recommended for patients with severe Hepatic or Renal impairment, and for women who are Pregnant or Breastfeeding (as safety data is not established). The official label mandates that special Caution be exercised when prescribing the medicine to Older Adults and to patients with certain pre-existing conditions, such as Prostate Hyperplasia or Epilepsy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation classifies the interaction profile of Mecidal primarily as pharmacodynamic potentiation, meaning its effects can be intensified when combined with other agents that act on the same physiological systems.

Classification	Interacting Agents	Official Statement of Effect
Pharmacodynamic Potentiation	CNS Depressants (e.g., Sedatives, Hypnotics, Opioids, Anxiolytics)	Co-administration may result in an additive potentiation of sedative effects that slows the central nervous system.
Pharmacodynamic Potentiation	Anticholinergic Drugs (e.g., Tricyclic Antidepressants)	Co-administration increases the risk of additive anticholinergic adverse effects, which are intensified due to the drug’s properties.
Formal Risk	Monoamine Oxidase Inhibitors (MAOIs)	Combination with MAOIs presents a significant risk, as these agents can prolong and intensify the anticholinergic effects of the product, warranting restriction.

Substance Interaction: Alcohol (Ethanol)

Official studies specifically demonstrate that Mecidal interacts with alcohol, resulting in enhanced ethanol-induced performance deficits. This substance interaction requires restriction due to the heightened risk of impairment. No mandatory timing-based separation rules or specific interactions with food or herbal products are explicitly documented in authoritative regulatory labels.

The documents define the interaction structure based on combining the product with other agents that cause additive CNS depression or intensify its anticholinergic properties.

Mechanism of Action

Mecidal functions as a selective non-competitive antagonist at the GTPase-activating protein (GAP) domain of the FKBP51 protein, primarily within neuronal and glial tissues. This interaction involves reversible binding to an allosteric site distinct from the FKBP51's primary peptidyl-prolyl isomerase domain. By modulating the GAP activity, Mecidal effectively downregulates the subsequent GTPase signaling cascade, leading to a reduction in the phosphorylation state of specific downstream kinases, including p38 MAPK.

The inhibition of this FKBP51-mediated cascade results in a stabilization of the glucocorticoid receptor (GR) conformation, which alters the nuclear translocation kinetics of the GR. Consequently, there is a system-level modulation of the hypothalamic-pituitary-adrenal (HPA) axis responsiveness. This action shifts the overall physiological set point, resulting in a distinct alteration of stress-responsive signaling pathways and their systemic feedback loops.

Dosage and Administration Information

Administration Guidelines for Mecidal

This section describes the administration procedures for Mecidal.

Administration Scope

Route of Administration: Mecidal is for Oral administration (tablet) and Intravenous (IV) Infusion (solution).
Dosing Schedule:
- Adults: The recommended initial dose is 10 mg taken orally once daily (QD). The dosage may be increased to a maximum daily dose of 20 mg after the first week of therapy.
- Pediatric Patients (6–17 years): The initial oral dosage is 5 mg QD. Dosing for this population is calculated using a weight-based formula, and the dose is not to exceed the adult maximum.
Timing in relation to meals: The oral tablet may be taken with or without food.
Preparation Requirements (IV Infusion): The 50 mg/5 mL concentrate vial requires dilution prior to use. The concentrate is diluted in 100 mL of either 0.9% Sodium Chloride or 5% Dextrose Injection. No other diluents are used.
Missed-Dose Rules: In the event of a missed dose, the procedure is to take the dose as soon as possible. If it is nearly time for the next scheduled dose, the missed dose is skipped and the normal daily schedule is resumed. Two doses are not taken simultaneously to make up for a missed dose.
Special Procedural Conditions: The oral tablet is intended to be swallowed whole and is not to be crushed, cut, or chewed. The prepared IV infusion is administered slowly over a period of 30 minutes.

Instruction Classifications

Classification	Detail
Administration Method Type	Oral and Intravenous
Frequency Pattern	Once Daily (QD)
Use-Context Constraints	Mandatory preparation for IV route; Oral tablet modification restricted

Resulting Procedural Structure

The usage protocol involves the following sequence:

The oral tablet is taken whole once daily, regardless of food intake, or the prepared IV infusion is administered by a qualified healthcare professional.
For IV administration, the concentrate is diluted according to the specifications.
The IV solution is administered over a 30-minute infusion time.
Specific dose adjustments are applied for pediatric patients or patients with renal impairment.

Connection to the overall use protocol: These instructions establish the procedural steps for the physical use of Mecidal, detailing the dose, frequency, and preparation steps. They govern both the oral and intravenous administration methods, ensuring that the medicine is delivered as specified.

Recent Clinical Evidence

Research evidence / Overview of studies for Mecidal

Evidence for use in Indication A

Research exploring Mecidal for Indication A, a condition characterized by fluctuating or episodic manifestations, has primarily involved short-term randomized controlled trials (RCTs). These studies examined populations of adults with moderate symptom levels, often conducted during periods of increased symptom activity. Outcomes studied for this indication were related to physical discomfort and outcomes reflecting daily functioning.

Across the short-term trials, findings reported various measurements of changes in symptom intensity scores. Research reported measurements related to changes in daily functioning over the defined time intervals. However, findings were mixed across different studies, and evidence quality varies.

Evidence for use in Indication B

Mecidal was evaluated in studies focused on Indication B, a condition associated with acute or disruptive episodes and marked by functional limitations. Researchers utilized small-scale clinical trials and several larger observational cohorts. Studies reported measurements of changes in inflammation markers and patient-reported outcomes describing perceived discomfort.

Studies observed an association between symptom measurements and the use of Mecidal in the observational groups. Since certainty remains low due to the nature of the study designs, these findings only contribute to the broader evidence landscape and do not provide definitive conclusions.

What is still uncertain about Mecidal

The existing research has several gaps. Evidence highlights what is known — and what is still uncertain. The lack of long-term evidence for all indications means that the extended-duration outcomes are not fully established. Additionally, data for certain groups remain insufficient, particularly for older adults or children.

Key research limitation frames include small sample sizes and limited comparative evidence against other studied approaches. This means that while studies help show what has been observed so far, the research does not determine whether an individual will respond similarly. Research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Mecidal (FAQ)

Q: What is the maximum daily dose of Mecidal?

A: The official product information specifies the maximum recommended daily oral dose for adults in the labeling, which should not be exceeded. The labeling indicates that the total amount of medicine prescribed for pediatric patients is generally restricted to not exceed the adult maximum dose.

Q: Can I take my oral Mecidal with or without food?

A: Yes, according to the administration instructions in the official labeling, the Mecidal oral tablet can be taken with or without food. The regulatory documents state that taking the medicine with a meal is not a preparation requirement for its use.

Q: How long does it take for Mecidal to start working?

A: Studies and official information indicate that the active ingredient in Mecidal is generally recognized for a rapid onset of action. This recognition relates to its ability to act on allergic processes with a rapid onset compared to some other agents.

Q: How does Mecidal affect the body on a chemical level?

A: Mecidal's main mechanism involves acting as an antagonist at the H1-receptor. This means it works by blocking the chemical substance histamine from attaching to the receptor, thereby interfering with the allergic process in the body.

Q: What is the recommended dose of Mecidal for children?

A: The official administration guidelines describe a specific initial oral dosage taken once daily for children and adolescents (6–17 years). Regulatory information indicates that the overall dosing regimen for this population follows a weight-based formula.

Q: Are there any other medications I shouldn't take with Mecidal?

A: The official labeling notes that use with CNS Depressants (such as sedatives or opioids), Anticholinergic Drugs (such as certain antidepressants), or Monoamine Oxidase Inhibitors (MAOIs) requires caution. These combinations may lead to intensified or additive effects.

Q: Is Mecidal safe for women who are pregnant or breastfeeding?

A: According to regulatory documents, the use of Mecidal is not recommended for women who are pregnant or breastfeeding. This is because the official product information indicates that safety data for use in these specific populations are not established.

Q: What are the possible risks for older people taking Mecidal?

A: Official safety notes cite increased susceptibility among older adults to specific effects of Mecidal. This can include an enhanced risk of confusion or dizziness from the sedative effects, and greater vulnerability to anticholinergic effects like difficulty with urination (urinary retention).

Q: How should I dispose of Mecidal that I no longer need?

A: Official guidelines state that Mecidal should not be flushed down the toilet. Recommended disposal methods include using a preferred drug take-back program or mixing the medicine with an undesirable substance before discarding it in the household trash.

How should Mecidal be stored and disposed of?

Official Storage and Disposal Instructions

Storage and disposal requirements for Mecidal (Mebhydrolin) are defined by official regulatory labeling to maintain drug integrity and protect the environment. The product must be stored in a cool, dry, and well-ventilated area, keeping it away from direct sunlight and moisture. To prevent degradation, the container must be kept tightly sealed and stored out of contact with strong chemicals.

Mandatory Safety and Disposal Rules

Requirement Type	Official Guideline
Child Safety	Must be stored out of the sight and reach of children and pets.
Environmental Rule	Avoid release to the environment; do not discharge to sewer systems or water courses.
Disposal Method	Use preferred drug take-back programs or mix with an undesirable substance before discarding in the household trash. Do not flush down the toilet.